- Published on:
Beijing, Aug 13 (Prensa Latina) The Cuba-China Biotech Pharmaceuticals Limited (BPL) joint venture is preparing to begin clinical trials here of the monoclonal antibody Itolizumab, of Cuban patent, which is used against autoimmune diseases.
